中文
On September 10, Shanghai LePure Biotech Co., Ltd. (“LePure Biotech”) and Beijing ACROBiosystems Co., Ltd. (“ACROBiosystems”) officially signed a strategic cooperation agreement.
The signing ceremony was attended by representatives from both companies, including Frank Wang, Co-founder and CEO of LePure Biotech, and Wang Tongtong, Vice President of LePure Biotech; as well as Chen Yiding, Founder, Chairman and CEO of ACROBiosystems; Miao Jingyun, Senior Vice President, Chief Operating Officer and Co-founder; and He Simin, Head of the Platform Ecosystem Business Unit and Senior Marketing Director.
The two companies will establish a long-term strategic partnership focused on cross-border supply chain and logistics for biopharmaceutical products. By combining LePure Biotech’s extensive expertise in single-use bioprocessing products and process solutions with ACROBiosystems’ strengths in global life science supply chain services and worldwide customer support, the two companies will explore new models for end-to-end collaboration and jointly support the high-quality global expansion of biopharmaceutical products.
Under the Strategic Cooperation Framework Agreement, the two parties will establish a long-term cooperation mechanism across multiple areas, including integrated cross-border logistics, overseas warehousing and order fulfillment, comprehensive overseas supply chain solutions, digitalization and intelligent supply chain management, as well as joint branding and industry influence building
Driven by technological innovation, LePure Biotech is committed to its mission of “Empowering Biopharma with High-Quality Process Solutions.” Over the past 15 years, the company has built deep expertise across the entire biopharmaceutical manufacturing process and has served more than 10,000 customers worldwide.
As the biopharmaceutical industry enters a new stage of global expansion, LePure Biotech will use this partnership as an opportunity to work with ACROBiosystems to build a more efficient, reliable, and compliant global supply chain. Together, the two companies aim to continuously translate systematic global delivery capabilities into greater value for customers and the industry, while accelerating the globalization of biopharmaceutical innovation.
